These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

880 related items for PubMed ID: 32391625

  • 1. Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.
    Akazawa Y, Saito Y, Yoshikawa T, Saito K, Nosaka K, Shimomura M, Mizuno S, Nakamoto Y, Nakatsura T.
    Cancer Sci; 2020 Aug; 111(8):2736-2746. PubMed ID: 32391625
    [Abstract] [Full Text] [Related]

  • 2. EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
    Yamada T, Azuma K, Muta E, Kim J, Sugawara S, Zhang GL, Matsueda S, Kasama-Kawaguchi Y, Yamashita Y, Yamashita T, Nishio K, Itoh K, Hoshino T, Sasada T.
    PLoS One; 2013 Aug; 8(11):e78389. PubMed ID: 24223798
    [Abstract] [Full Text] [Related]

  • 3. A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
    Ofuji K, Tada Y, Yoshikawa T, Shimomura M, Yoshimura M, Saito K, Nakamoto Y, Nakatsura T.
    Int J Oncol; 2015 Feb; 46(2):497-504. PubMed ID: 25532027
    [Abstract] [Full Text] [Related]

  • 4. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer.
    Park W, Wei S, Xie CL, Han JH, Kim BS, Kim B, Jin JS, Yang ES, Cho MK, Ryu D, Yang HX, Bae SJ, Ha KT.
    Exp Mol Med; 2024 May; 56(5):1137-1149. PubMed ID: 38689087
    [Abstract] [Full Text] [Related]

  • 5. Activation of insulin-like growth factor-1 receptor confers acquired resistance to osimertinib in non-small cell lung cancer with EGFR T790M mutation.
    Hayakawa D, Takahashi F, Mitsuishi Y, Tajima K, Hidayat M, Winardi W, Ihara H, Kanamori K, Matsumoto N, Asao T, Ko R, Shukuya T, Takamochi K, Hayashi T, Suehara Y, Takeda Nakamura I, Ueno T, Kohsaka S, Mano H, Takahashi K.
    Thorac Cancer; 2020 Jan; 11(1):140-149. PubMed ID: 31758670
    [Abstract] [Full Text] [Related]

  • 6. LS-106, a novel EGFR inhibitor targeting C797S, exhibits antitumor activities both in vitro and in vivo.
    Liu Y, Lai M, Li S, Wang Y, Feng F, Zhang T, Tong L, Zhang M, Chen H, Chen Y, Song P, Li Y, Bai G, Ning Y, Tang H, Fang Y, Chen Y, Lu X, Geng M, Ding K, Yu K, Xie H, Ding J.
    Cancer Sci; 2022 Feb; 113(2):709-720. PubMed ID: 34855271
    [Abstract] [Full Text] [Related]

  • 7. Response to Brigatinib Targeted Therapy in Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 19 Deletion, T790M, and cis-C797S Triple Mutations: A Case Report.
    Chen ZW, Lin G, Shih HJ, Wu CE.
    Int J Mol Sci; 2022 Dec 29; 24(1):. PubMed ID: 36614045
    [Abstract] [Full Text] [Related]

  • 8. BBT-176, a Novel Fourth-Generation Tyrosine Kinase Inhibitor for Osimertinib-Resistant EGFR Mutations in Non-Small Cell Lung Cancer.
    Lim SM, Fujino T, Kim C, Lee G, Lee YH, Kim DW, Ahn JS, Mitsudomi T, Jin T, Lee SY.
    Clin Cancer Res; 2023 Aug 15; 29(16):3004-3016. PubMed ID: 37249619
    [Abstract] [Full Text] [Related]

  • 9. Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
    Ariyasu R, Uchibori K, Sasaki T, Tsukahara M, Kiyotani K, Yoshida R, Ono Y, Kitazono S, Ninomiya H, Ishikawa Y, Mizukami Y, Yanagitani N, Fujita N, Nishio M, Katayama R.
    Cancer Sci; 2021 Jun 15; 112(6):2371-2380. PubMed ID: 33686722
    [Abstract] [Full Text] [Related]

  • 10. Let-7c regulated epithelial-mesenchymal transition leads to osimertinib resistance in NSCLC cells with EGFR T790M mutations.
    Li XF, Shen WZ, Jin X, Ren P, Zhang J.
    Sci Rep; 2020 Jul 08; 10(1):11236. PubMed ID: 32641854
    [Abstract] [Full Text] [Related]

  • 11. Acquired EML4-ALK fusion and EGFR C797S in cis mutation as resistance mechanisms to osimertinib in a non-small cell lung cancer patient with EGFR L858R/T790M.
    Wang LS, Chen SQ, Zhong X, Jiao XD, Liu K, Qin BD, Wu Y, Ling Y, Duan XP, Zang YS.
    Anticancer Drugs; 2023 Nov 01; 34(10):1146-1150. PubMed ID: 36728908
    [Abstract] [Full Text] [Related]

  • 12. EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.
    Rangachari D, To C, Shpilsky JE, VanderLaan PA, Kobayashi SS, Mushajiang M, Lau CJ, Paweletz CP, Oxnard GR, Jänne PA, Costa DB.
    J Thorac Oncol; 2019 Nov 01; 14(11):1995-2002. PubMed ID: 31377341
    [Abstract] [Full Text] [Related]

  • 13. Acquired resistance to osimertinib in patients with non-small-cell lung cancer: mechanisms and clinical outcomes.
    Mu Y, Hao X, Xing P, Hu X, Wang Y, Li T, Zhang J, Xu Z, Li J.
    J Cancer Res Clin Oncol; 2020 Sep 01; 146(9):2427-2433. PubMed ID: 32385709
    [Abstract] [Full Text] [Related]

  • 14. Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines.
    Dal Maso A, Lorenzi M, Ferro A, Pilotto S, Cecere F, Follador A, Polo V, Del Conte A, Sartori G, Giavarra M, Scattolin D, Indraccolo S, Frega S, De Maglio G, Menis J, Bonanno L, Calabrese F, Guarneri V, Conte P, Pasello G.
    Future Oncol; 2021 Jul 01; 17(19):2513-2527. PubMed ID: 33988036
    [Abstract] [Full Text] [Related]

  • 15. Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre.
    Suryavanshi M, Jaipuria J, Mattoo S, Dhandha S, Khatri M.
    Clin Oncol (R Coll Radiol); 2022 Nov 01; 34(11):e451-e462. PubMed ID: 35810049
    [Abstract] [Full Text] [Related]

  • 16. EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancer.
    Wang S, Tsui ST, Liu C, Song Y, Liu D.
    J Hematol Oncol; 2016 Jul 22; 9(1):59. PubMed ID: 27448564
    [Abstract] [Full Text] [Related]

  • 17. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
    Li Y, Zang H, Qian G, Owonikoko TK, Ramalingam SR, Sun SY.
    Cancer; 2020 Mar 15; 126(6):1339-1350. PubMed ID: 31821539
    [Abstract] [Full Text] [Related]

  • 18. Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S.
    Assadollahi V, Rashidieh B, Alasvand M, Abdolahi A, Lopez JA.
    J Cell Biochem; 2019 Aug 15; 120(8):13046-13055. PubMed ID: 30916819
    [Abstract] [Full Text] [Related]

  • 19. Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC).
    Zhang Y, Tong L, Yan F, Huang P, Zhu CL, Pan C.
    Bioorg Chem; 2024 Jun 15; 147():107394. PubMed ID: 38691906
    [Abstract] [Full Text] [Related]

  • 20. Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.
    Miyashita Y, Ko R, Shimada N, Mitsuishi Y, Miura K, Matsumoto N, Asao T, Shukuya T, Shibayama R, Koyama R, Takahashi K.
    Thorac Cancer; 2021 Feb 15; 12(3):329-338. PubMed ID: 33219754
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.